Clarity Pharmaceuticals has secured investigational new drug approval (IND) from the U.S. Food and Drug Administration (FDA) to start a phase II clinical trial of a radiotracer for detecting cancer in asymptomatic patients.
The clearance is for Clarity's SAR-Bombesin agent, which detects prostate cancer in men who are prostate specific membrane antigen (PSMA)-negative, according to the firm. The trial, called Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer trial (SABRE), will include up to 50 PSMA-negative men who have biochemical recurrence of the disease after surgery or radiation.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
